Chinook Therapeutics Past Earnings Performance
Past criteria checks 0/6
Chinook Therapeutics's earnings have been declining at an average annual rate of -41.1%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 49% per year.
Key information
-41.1%
Earnings growth rate
60.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 49.0% |
| Return on equity | -68.8% |
| Net Margin | -4,199.9% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?
May 28
Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth
Feb 14Chinook Therapeutics: Multiple Shots On Goal For IgAN
Aug 31Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%
Aug 12Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line
Aug 08Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease
Jul 05Revenue & Expenses Breakdown
How Chinook Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 6 | -246 | 44 | 0 |
| 31 Mar 23 | 5 | -216 | 40 | 0 |
| 31 Dec 22 | 6 | -188 | 36 | 0 |
| 30 Sep 22 | 57 | -118 | 34 | 0 |
| 30 Jun 22 | 54 | -92 | 31 | 0 |
| 31 Mar 22 | 54 | -97 | 30 | 0 |
| 31 Dec 21 | 52 | -103 | 32 | 0 |
| 30 Sep 21 | 1 | -160 | 35 | 0 |
| 30 Jun 21 | 1 | -149 | 31 | 0 |
| 31 Mar 21 | 1 | -114 | 27 | 0 |
| 31 Dec 20 | 1 | -82 | 19 | 0 |
| 30 Sep 20 | 0 | -52 | 8 | 0 |
| 30 Jun 20 | 0 | -54 | 6 | 1 |
| 31 Mar 20 | 0 | -48 | 2 | 2 |
| 31 Dec 19 | 0 | -47 | 2 | 6 |
Quality Earnings: KDNY is currently unprofitable.
Growing Profit Margin: KDNY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KDNY is unprofitable, and losses have increased over the past 5 years at a rate of 41.1% per year.
Accelerating Growth: Unable to compare KDNY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KDNY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: KDNY has a negative Return on Equity (-68.8%), as it is currently unprofitable.